Archives

GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer

GENEVA—Toxicities from targeted agents used in lung cancer differ from those encountered with other drugs but can be managed successfully if recognized early and treated. At the European Lung Cancer C

GENEVA—The potential for using vaccines as important weapons against non small cell lung cancer has not yet been realized according to Johan Vansteenkiste MD PhD, an oncologist and professor of medici

VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-K

VIENNA—Obesity and insulin resistance were named as important targets for primary prevention of breast cancer by Pamela J. Goodwin, MD, MSc, FRCPC, Professor of Medicine and Director of the Marvelle K

VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of th

VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the Univers

VIENNA—Because harnessing the immune system is now proven as a way of managing breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes, according to Giuseppe Curigliano MD

VIENNA—Understanding the emerging genomic landscape of breast cancer needed international research including large molecular screening projects—according to Peter Campbell MD PhD, head of Cancer Genet

VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Confer

VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from th

VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Bre

VIENNA—Estrogen receptor negative breast cancer might be prevented by strategies under investigation including HER2-targeting, vaccination and treatment with metformin or retinoids. Powel Brown MD, Ch

VIENNA—Latest research on breast cancer prevention was reported at the 20125 St Gallen breast cancer conference in a session concluded by Jack Cuzick, PhD, Director of the Wolfson Institute of Prevent

ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch

SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powle

SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific su

SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2

SAN FRANCISCO—The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies — ju

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a